The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for ...

Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

Ogsiveo ™ met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

OGSIVEO is a highly innovative therapy with efficacy data demonstrating both meaningful antitumor activity and a significant improvement in desmoid tumor symptoms,” said Mrinal M. Gounder, M.D ...

Evercore ISI initiated coverage of Immunome (IMNM) with an Outperform rating and $18 price target The company is developing a deep ADC pipeline ...

Corinne Jenkins has given her Buy rating due to a combination of factors surrounding the optimistic outlook for Springworks Therapeutics’s new drug, Ogsiveo. Her confidence is largely influenced ...